Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA lessened its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 36.2% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 43,006 shares of the company's stock after selling 24,398 shares during the quarter. Massachusetts Financial Services Co. MA owned approximately 0.06% of Nurix Therapeutics worth $511,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of NRIX. FMR LLC increased its position in Nurix Therapeutics by 1,711.9% in the fourth quarter. FMR LLC now owns 10,634,231 shares of the company's stock worth $200,349,000 after purchasing an additional 10,047,329 shares during the last quarter. RA Capital Management L.P. bought a new stake in Nurix Therapeutics during the fourth quarter worth approximately $25,120,000. Soleus Capital Management L.P. increased its stake in Nurix Therapeutics by 97.3% during the fourth quarter. Soleus Capital Management L.P. now owns 2,102,833 shares of the company's stock worth $39,617,000 after acquiring an additional 1,036,999 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Nurix Therapeutics during the fourth quarter worth approximately $16,447,000. Finally, Boxer Capital Management LLC bought a new stake in Nurix Therapeutics during the fourth quarter worth approximately $10,608,000.

Analyst Ratings Changes

Several research firms have commented on NRIX. Stephens reaffirmed an "overweight" rating and set a $30.00 price objective on shares of Nurix Therapeutics in a research note on Thursday, July 10th. Wall Street Zen raised shares of Nurix Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, June 21st. Stifel Nicolaus dropped their price objective on shares of Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating for the company in a research note on Wednesday, April 9th. Wells Fargo & Company dropped their price objective on shares of Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating for the company in a research note on Wednesday, April 9th. Finally, UBS Group dropped their price objective on shares of Nurix Therapeutics from $30.00 to $26.00 and set a "buy" rating for the company in a research note on Thursday, July 10th. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $29.31.

Nurix Therapeutics Trading Down 0.1%

Shares of Nurix Therapeutics stock traded down $0.01 during trading on Friday, hitting $11.52. 476,863 shares of the stock traded hands, compared to its average volume of 976,305. Nurix Therapeutics, Inc. has a 52-week low of $8.18 and a 52-week high of $29.56. The stock's fifty day simple moving average is $11.64 and its 200 day simple moving average is $13.33. The firm has a market cap of $880.69 million, a P/E ratio of -4.41 and a beta of 2.15.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.79) by $0.27. The business had revenue of $44,056 billion during the quarter, compared to analysts' expectations of $16.26 million. Nurix Therapeutics had a negative net margin of 234.57% and a negative return on equity of 45.26%. As a group, equities analysts expect that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Insider Transactions at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,377 shares of the business's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total transaction of $38,835.50. Following the completion of the sale, the insider directly owned 61,516 shares in the company, valued at approximately $707,434. The trade was a 5.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Houte Hans Van sold 6,198 shares of the business's stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $11.33, for a total value of $70,223.34. Following the sale, the chief financial officer owned 33,724 shares of the company's stock, valued at approximately $382,092.92. This trade represents a 15.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 12,013 shares of company stock valued at $137,096 in the last ninety days. 7.40% of the stock is currently owned by insiders.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.